Onxeo S.A. announced that the Company has entered into a Clinical Research Agreement with Gustave Roussy, the leading European cancer center, to conduct the REVOCAN1 phase 1b/2 study designed to evaluate the effect of AsiDNATM, Onxeo's first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib in its approved indication for 2nd line maintenance treatment of relapsed ovarian cancer.